[3] Vrints C, Andreotti F, Koskinas K C, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes [J]. Eur Heart J, 2024, 45(36): 3415-3537. DOI: 10.1093/eurheartj/ehae177. [4] Ma...
胆固醇吸收抑制剂因其在优化血脂管理,尤其是降低低密度脂蛋白胆固醇(LDL-C)幅度方面独特优势与临床应用价值,受到广泛关注。在2024年美国心脏病协会(AHA)年会上一项关于胆固醇吸收抑制剂的最新系统性回顾与荟萃分析引起了热烈讨论。该研究比较...
[11].Byrne, Robert A et al. “2023 ESC Guidelines for the management of acute coronary syndromes.” European heart journal vol. 44,38 (2023): 3720-3826. [12].Comparison Of An “Inclisiran First” Strategy With Usual Care In Patients With Atherosclerotic Cardiovascular Disease: Results From ...
LDL Cholesterol Ranges Lower numbers are better when it comes to LDL cholesterol test results. The general guidelines for adults in the U.S. are: Less than 100 milligrams per deciliter (mg/dL): Optimal 100-129 mg/dL: Near or above optimal ...
Over the years, there have been significant changes to the dyslipidemia medication management guidelines, alongside increasing evidence for novel cholesterol-lowering medications, including PCSK9 inhibitors. News March 27, 2025 3 min read Save
Guidelines. Circulation 2019, 139(25):e1082-e1143. 声明:本文仅供医疗卫生专业人士了解最新医药资讯参考使用,不代表本平台观点。该信息不能以任何方式取代专业的医疗指导,也不应被视为诊疗建议,如果该信息被用于资讯以外的目的,本站及作者不承担相关责任。
[22]Robert A Byrne, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023 Aug 25;ehad191. doi: 10.1093/eurheartj/ehad191. [23]Nikolaus Marx, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur He...
ESC Guidelines for the management of acute coronary syndromes in patients presenting withou t persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)...
The article discusses the importance of accurately predicting atherosclerotic cardiovascular disease (ASCVD) risk and the role of cholesterol-related information in risk prediction models. It highlights the three cholesterol measures recommended by guidelines: apolipoprotein B (apoB), non-high-density ...
2006). These observations, coupled to the results of clinical trials testing the most recent lipid-lowering drugs (i.e., PCSK9 inhibitors), which have shown that LDL-C levels may be lowered well below the values recommended by guidelines without safety concerns (Robinson et al. 2017; ...